The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
In a revised medical policy, Aetna said it would continue to cover NIPT for high-risk pregnancies, but not average-risk ones.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
Natera said that the new product would further establish the company as a one-stop shop in the reproductive health market from pre-pregnancy through birth.
Natera's testing volumes increased but revenues declined due to achieving in-network status with payors and being reimbursed at a lower rate.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
The GW Index outperformed the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
Natera discussed its plans to move into the whole-genome newborn screening market and provided updates on its NIPT and oncology businesses.
Natera saw total Q4 2016 revenues decline to $49.3 million, despite an increase in testing volumes.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.